Info page - Autism
and heavy metal toxity
Nontoxic Oral Clathration Agent Shown to Perform
Better than, or Equal to, DMSA and DMPA
Parents of autistic children who suspect heavy metal toxicity as a contributor to their
child’s condition may find a nontoxic oral clathration agent will perform as well as
or better than typically used chelating agents, according to a report in the nationally
respected consumer journal, The Doctors’ Prescription for Healthy Living.
The report—published in the February edition—details the experience of a Troy,
Michigan, couple whose child was diagnosed with autism that may have resulted from or been
exacerbated by such toxicity. The couple notes that the oral clathration agent proved to
be as effective as their son’s DMSA/DMPS treatments, yet without side effects.
Autistic children may be prescribed dimercaptosuccinic acid (DMSA) or dimercaptopropane
sulfonate (DMPS) if heavy metal toxicity is suspected. However, a combination of the oral
clathration agent and ionic mineral supplements increased their child’s heavy metal
output by two to three times (as measured by urinalysis). The couple is quoted as telling
the publication, “In two months, we had the same benefits with PCA-Rx
and ionic minerals as using DMSA for an entire year. Also, unlike DMSA, PCA-Rx will not
chelate beneficial minerals, one reason it is less stressful to the child’s
body.”
“This information is important to parents of autistic children,” notes publisher
and editor David Steinman. “Many of the treatments afforded to children have some
toxicity associated with them and stress the child. Based on our current report and past
reports, we believe that oral clathration is certainly an option that parents should know
about.”
Steinman notes that while conventional oral chelation therapy may be described as one
dimensional, oral clathration is a three-dimensional process. In this case, specifically
sequenced glycoproteins and peptides form a lattice or inclusion complex and multiple
receptor sites that attach to a toxic molecule with irreversible bonds, literally wrapping
around the toxic substance to prevent additional reactions with tissues or organs as it is
eliminated from the body.
Unlike the ionic bond utilized to transport metals from the body with chelation,
clathration utilizes ionic, covalent and hydrogen bonds. Not one but three major types of
bonds at multiple points are created.
“The product that we mentioned—PCA-Rx—has
a very high bonding affinity for heavy metals,” notes Steinman. “Most toxins or
heavy metals that attach to cell receptors do so in a manner that is competitively
reversible, so if molecules like those in PCA-Rx come along with greater affinity, the
toxins can be dislodged from the receptors. Because of the formula’s tremendous
affinity for heavy metals, this is an improvement over chelation therapy, which has a much
more difficult time removing heavy metals from cell receptors.”
“We want parents of autistic children and groups dedicated to helping such children
and adults to know about oral clathration because it is a viable and important
option,” adds Steinman.
He adds, “Few proven treatments are available to autistic children. What we do know
is that heavy metal toxicity may sometimes be part of the pathology. Testing for heavy
metal burden is essential. PCA-Rx has been successfully used with autistic children to
safely accelerate detoxification. While additional clinical studies are desired, we know
that PCA-Rx is safe and efficacious. It is an important healing pathway that parents of
autistic children should know about.”
Steinman, a nationally recognized consumer advocate, is available for interviews and may
be contacted at (800) 959-9797.
For individuals or organizations wishing to learn more about oral clathration, they should
contact ASN™/MAXAM™ Nutraceutics™ toll-free at (800) 800-9119.
Maxam Nutraceutics
1813 Cascade Avenue
Hood River, Oregon 97031
USA
(800) 800-9119 PHONE
(541) 387-4503 FAX
Email: sales@maxamlabs.com
www.maxamlabs.com
